Picard Medical Secures Innovative Patents for Heart Technology
- Patent portfolio secures innovation for the future of heart replacement -
Strengthening Intellectual Property
Picard Medical, Inc., parent company of SynCardia Systems LLC, is making significant strides in the field of heart replacement technology. Recently, they announced the award of U.S. Patent No. 12,383,722 B2 related to their innovative SynCardia Total Artificial Heart (STAH), known as the "Emperor." This patent is pivotal as it enhances the framework of their previously acquired patents, cementing their leadership in the market.
Advancements Through Patents
The newly granted patent introduces advanced systems and methods for a next-generation total artificial heart, providing enhanced patient flexibility and comfort. The Emperor builds on their existing technological framework and offers promising solutions for patients suffering from severe heart failure. Currently, Picard Medical holds 34 unique patented claims across three patents in the United States for their total artificial heart system, along with a corresponding patent in China that supports their international ambitions.
Commitment to Innovation
Matt Schuster, COO of SynCardia, shared insights on the company's dedicated efforts. "Our growing patent portfolio underscores SynCardia's commitment to advancing our life-saving technology," Schuster stated. He emphasized that the Emperor signifies the future of heart failure treatment, and the expansion of their patents is a strategic foundation for international market growth. The goal is to create a robust environment for their next-generation heart solutions—a commitment to innovation that resonates throughout the industry.
Building a Global Presence
Picard Medical aims to extend its patent protection on a global scale. Their focus is on advancing durable mechanisms, operational efficiency, and revolutionary wireless features that are set to redefine heart replacement solutions. As they continue to innovate, the company also seeks to secure its technological advancements to maintain and grow its presence worldwide.
Customer-Centric Solutions
Patrick NJ Schnegelsberg, CEO of SynCardia, expressed his vision for the future: "We are building the foundation for SynCardia's future by developing the world's first fully implantable, durable, and patient-friendly total artificial heart. Our patent portfolio secures the path from development to commercialization and positions us to help shape the future of heart replacement worldwide." This commitment to patient-friendly solutions marks a significant evolution in heart failure treatment.
About Picard Medical and Its Vision
Picard Medical, Inc. stands at the forefront of cardiac innovation as the parent company of SynCardia Systems, LLC, which is recognized as the leader in commercially available total artificial heart technology. Designed primarily for patients with end-stage heart failure, the SynCardia Total Artificial Heart has undergone extensive studies and has been successfully implanted in over 2,100 patients across 27 countries. This distinction establishes the STAH as the most utilized artificial heart globally.
Contact Information and Future Outlook
For those seeking to learn more about the revolutionary advances in heart technology being made by Picard Medical, they can reach out directly through their investor contact, Eric Ribner, Managing Director at LifeSci Advisors, who is available via email. Picard Medical promotes an open dialogue about its innovative projects and future plans, ensuring transparency and engagement with the public.
Frequently Asked Questions
What is the significance of the new patent awarded to Picard Medical?
The new patent secures innovative methods and systems for the next-generation total artificial heart, enhancing patient comfort and flexibility.
How many patents does Picard Medical hold for its heart technology?
Picard Medical currently holds 34 unique patented claims across three patents in the U.S. for its total artificial heart system and a corresponding patent in China.
What does the "Emperor" represent for patients?
The Emperor is designed to be fully implantable, offering pulsatile flow capability without needing external support, improving patient quality of life.
Who can be contacted for more information about Picard Medical?
Interested parties can contact Eric Ribner at LifeSci Advisors or use their investor relations email for inquiries about ongoing innovations.
What are the future goals for Picard Medical?
Picard Medical aims to expand its global presence and continue protecting its innovative heart technology to lead the market in patient-friendly solutions.
